Stefan Glück | Vice President of Global Medical Affairs
Celgene | United States of America

Stefan Glück, Vice President of Global Medical Affairs, Celgene

Stefan Glück, MD, PhD, is V.P of Global Medical Affairs, at Celgene Corporation since October 2014, and a medical oncologist with focus on breast cancer. He has overseen breast, ovarian, pancreatic and bladder cancer activities worldwide, as well as the Immuno-Oncology Program in solid tumors. Recently, his job requirements have shifted to include all solid tumors and most importantly Early Assets.

He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. 

Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. 
He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada. 

Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.

He is a member of such prestigious professional organizations, as the American Society of Clinical Oncology, European Society for Medical Oncology, American & European Association of Cancer Research, and the International Association for Breast Cancer Research. He is a reviewer of numerous journals e.g.: Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, Clinical Breast Cancer and many others. He was Medical Associate Editor of Breast Cancer Research & Treatment and Co-Editor in Chief of Journal of Carcinogenesis and Clinical Communications Oncology that he co-founded in 2014.

He has authored or co-authored over 260 articles. In addition, Dr Glück has written or co-written several book chapters and numerous journal abstracts, and has presented more than 350 papers at national and international meetings.

Appearances:



Phar-East Day 1 @ 14:20

Big pharma perspectives: Using global pipeline development to serve Asia’s population

last published: 26/Sep/18 02:35 GMT

back to speakers

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738